CAR-T efficacy: is conditioning the key?
- PMID: 31023743
- DOI: 10.1182/blood-2019-03-900928
CAR-T efficacy: is conditioning the key?
Conflict of interest statement
Conflict-of-interest disclosure: S.S.N. has received research support from Kite/Gilead, Celgene, Cellectis, Poseida, Merck, Acerta, Karus, BMS, and Unum Therapeutics and served as consultant and advisory board member for Kite/Gilead, Celgene, Novartis, Unum Therapeutics, Pfizer, Merck, Precision Biosciences, CellMedica, and Incyte.
Comment on
-
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.Blood. 2019 Apr 25;133(17):1876-1887. doi: 10.1182/blood-2018-11-887067. Epub 2019 Feb 19. Blood. 2019. PMID: 30782611 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources

